These days, Prof. Jiang Hulin's team from our school publish the latest researches of medical devices for blood purification of circulating tumour cells and tumour exosomes in Advanced Science (IF: 15.1) and Biosensors & Bioelectronics (IF: 12.6) successively.
Tumour metastasis has become the main cause of about 90 % of cancer-related deaths, and circulating tumour cells (CTCs) are the vital component in the metastatic process, so as an important biomarker for non-invasive clinical diagnosis and prognostic assessment, the detection and clearance of CTCs are important in predicting overall and progression-free survival of cancer patients. However, existing techniques for the isolation and detection of CTCs are limited to small volumes of blood samples, which fail in full reflection of CTCs’hematological distribution throughout the body. Inspired by hemodialysis devices, Prof. Hulin Kang's team has developed a medical device to specifically remove circulating tumor cells in whole blood to achieve effective purification of circulating tumor cells. This study is published in Biosensors & Bioelectronics,2023,232:115292, under the title A novel whole blood purifier for efficient capture and separation of circulating tumor cells. A novel whole blood purifier for efficient capture and separation of circulating tumour cells. Associate Professor Xing Lei, Wang Xing (M.S. Student of Class 2021), Mingtao Yu (M.S. Student of Class 2022) and He Yujing (PhD Student of Class 2019) are the co-first authors. Prof. Jiang is the independent corresponding author and CPU is the unique correspondence affiliation of this article.
Original link:https://www.sciencedirect.com/science/article/abs/pii/S0956566323002348
Growing evidence shows that tumour exosomes (TDEs, 30-150 nm in size), which are small extracellular vesicles secreted by tumour cells, are also responsible for tumour metastasis. Prof. Jiang Hulin's team further develops a pro-metastatic derivatives eliminator (PMDE), which effectively captures and removes CTCs and TDEs from peripheral blood, showing a superior biocompatibility (Fig. 2). This research is published under the title “A pro-metastatic derivatives eliminator for in vivo dual-removal of circulating tumor cells and tumor-derived exosomes impedes their biodistribution into distant organs” in Advanced Science 2023: e2304287 (doi:10.1002/advs.202304287). Ying Sun (M.S. Student of Class 2023) and Associate Prof. Lei Xing of the Department of Pharmacy are the co-first authors, and Prof. Jiang is the independent corresponding author. CPU is the unique correspondence affiliation.
Original link: http://doi.org/10.1002/advs.202304287
At present, Prof. Jiang's team focuses on the development of blood purification technology and has achieved accomplishments in the field of circulating tumour cell purification, with one utility model patent authorized and four invention patents applied for. In addition, the team has been actively looking for cooperative enterprises to co-develop blood purification medical devices (including but not limited to circulating tumour cells and tumour exosomes), in order to achieve early transformation of scientific and technological achievements.
These studies have been sponsored by major projects of the Ministry of Science and Technology, Key International (Regional) Cooperation and Exchange Projects and Top-level projects of the National Natural Science Foundation of China, as well as research projects of the National Key Laboratory of Multi-target Natural Drugs of China Pharmaceutical University.
